EMAS position statement: Testosterone replacement therapy in the aging male

Dimopoulou C., Ceausu I., Depypere H., Lambrinoudaki I., Mueck A., Perez-Lopez F. R., ...More

MATURITAS, vol.84, pp.94-99, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 84
  • Publication Date: 2016
  • Doi Number: 10.1016/j.maturitas.2015.11.003
  • Journal Name: MATURITAS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.94-99
  • Istanbul University Affiliated: Yes


Introduction: Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, characterized by the presence of symptoms (most usually of a sexual nature, such as decreased libido, decreased spontaneous erections and erectile dysfunction) and signs, in combination with low serum testosterone concentrations. Whether testosterone replacement therapy (TRT) should be offered to those individuals is still under extensive debate.